Lexicon Pharmaceuticals | LXRX - Creditori Commerciali





Creditori Commerciali Cambiamento Data
Abbott USD 4.12B 183M 2025-09
Acadia Pharmaceuticals USD 10.9M 10.84M 2025-12
Agios Pharmaceuticals USD 18.36M 1.2M 2025-12
Akebia Therapeutics USD 21.18M 11.1M 2025-12
Alnylam Pharmaceuticals USD 115.72M 1.87M 2025-12
AstraZeneca USD 25.28B 252M 2025-12
BioMarin Pharmaceutical USD 759.03M 39.41M 2025-12
Coherus Biosciences USD 9.91M 14.98M 2025-12
Eli Lilly USD 5.38B 1.12B 2025-12
Esperion Therapeutics USD 65.07M 12.44M 2025-12
Halozyme Therapeutics USD 20.9M 5.54M 2025-12
Illumina USD 240M 22M 2025-12
Insmed USD 79.91M 316K 2025-12
Ironwood Pharmaceuticals USD 1.61M 224K 2025-09
J&J USD 11.99B 2.37B 2025-12
Lexicon Pharmaceuticals USD 3.08M 714K 2025-12
MacroGenics USD 4.79M 1.15M 2025-12
MannKind USD 9.03M 1.76M 2025-12
Merck USD 4.15B 102M 2025-09
Moderna USD 317M 50M 2025-12
Novartis USD 4.46B 99M 2025-12
PTC Therapeutics USD 45.49M 8.87M 2025-12
Puma Biotechnology USD 6.39M 962K 2025-09
Sarepta Therapeutics USD 280.84M 186.83M 2025-12
Thermo Fisher Scientific USD 3.62B 502M 2025-12
Ultragenyx Pharmaceutical USD 40.57M 6.33M 2025-09
United Therapeutics USD 7.1M 460.9M 2025-12
Vanda Pharmaceuticals USD 39.09M 33.28M 2024-12